ArticleWorld journal of gastroenterology2017
Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.
Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis.Lipids in health and disease · 2024Pooled it
- Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Effect of Hepatitis C Virus Genotype, Cirrhosis, and Viral Cure on Serum Phosphatidylinositol Species Profiles.Biomedicines · 2025Article
- Clearance of Hepatitis C Viremia During Direct-Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism.Alimentary pharmacology & therapeutics · 2025Article
- Article
- Serum Phosphatidylcholine Species 32:0 as a Biomarker for Liver Cirrhosis Pre- and Post-Hepatitis C Virus Clearance.International journal of molecular sciences · 2024Article
- Changes in the Lipid Asset of HIV/HCV Patients after a Successful Course of Direct-Acting Antivirals.Journal of clinical medicine · 2024Article
- Lipid Profile and Cardiovascular Risk Modification after Hepatitis C Virus Eradication.Pathogens (Basel, Switzerland) · 2024Review
- Article
- Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance.International journal of molecular sciences · 2024Article
- Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China.Infectious diseases and therapy · 2023Article
- Changes in Components of Metabolic Syndrome after Antiviral Eradication in Hepatitis C Virus Infection.Life (Basel, Switzerland) · 2023Article
- Observational
- Evaluation of the effect of direct-acting antiviral agents on melatonin level and lipid peroxidation in chronic hepatitis C patients.Frontiers in pharmacology · 2023Article
- HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV.Biomedicines · 2022Article
- Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease.Journal of clinical medicine · 2022Article
- Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response.Diagnostics (Basel, Switzerland) · 2022Article
- Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.Internal medicine (Tokyo, Japan) · 2021Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the influence of interferon-free antivirus therapy on lipid profiles in chronic hepatitis C virus genotype 1b (HCV1b) infection.
methodsInterferon-free antiviral agents were used to treat 276 patients with chronic HCV1b infection, and changes in serum lipids of those who achieved sustained virologic response (SVR) were examined. The treatment regimen included 24 wk of daclatasvir plus asunaprevir (DCV + ASV) or 12 wk of sofosbuvir plus ledipasvir (SOF + LDV). SVR was achieved in 121 (85.8%) of 141 patients treated with DCV + ASV and 132 (97.8%) of 135 patients treated with SOF + LDV. In the two patient groups (DCV + ASV-SVR and SOF + LDV-SVR), serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides were measured at baseline during treatment and at 4 and 12 wk after treatment. Then, longitudinal changes in lipid profiles were analyzed.
resultsSerum levels of TC, LDL-C, and HDL-C were significantly increased throughout the observation period in both the DCV + ASV-SVR and SOF + LDV-SVR groups. During antivirus treatment, the increases in TC and LDL-C were significantly greater in the SOF + LDV-SVR group than in the DCV + ASV-SVR group (
conclusionSerum cholesterol significantly increased during SOF + LDV treatment. After treatment, HCV elimination was associated with a similar increase in cholesterol regardless of the therapy protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.